Oncology Advances in breast cancer: What’s new from ESMO 2025 ESMO 2025 showcased the breadth and urgency of breast cancer research, which remains one of the most diagnosed malignancies worldwide.
Oncology ESMO25: Acceleration, accessibility, and accuracy, with Barr... At ESMO25, pharmaphorum spoke with Barry Vucsko, Senior VP of Strategic Development, Agency Services, for the EVERSANA Oncology Centre of Excellence.
Oncology ESMO25: Transforming the cancer immunotherapy field, with Po... Onsite at ESMO 2025 in Berlin, pharmaphorum spoke with Poolbeg's Liam Tremble about their work on CRS in relapsed/refractory multiple myeloma.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.